| Dr Zachary David Jacobs, MD | |
|
4440 Broadway Blvd, Kansas City, MO 64111-3315 | |
| (816) 531-0930 | |
| (816) 531-2807 |
| Full Name | Dr Zachary David Jacobs |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 18 Years |
| Location | 4440 Broadway Blvd, Kansas City, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215033840 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 2009010345 (Missouri) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas City Physician Partners Inc | 7911132139 | 15 |
News Archive
Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.
Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.
Children are less likely to be diagnosed with crossed eyes, a condition known as strabismus, if they live in poor communities, according to an analysis led by researchers at the University of Michigan's Kellogg Eye Center.
In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.
› Verified 4 days ago
| Entity Name | Kansas City Physician Partners Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831531466 PECOS PAC ID: 7911132139 Enrollment ID: O20131031000394 |
News Archive
Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.
Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.
Children are less likely to be diagnosed with crossed eyes, a condition known as strabismus, if they live in poor communities, according to an analysis led by researchers at the University of Michigan's Kellogg Eye Center.
In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Zachary David Jacobs, MD 4440 Broadway Blvd, Kansas City, MO 64111-3315 Ph: (816) 531-0930 | Dr Zachary David Jacobs, MD 4440 Broadway Blvd, Kansas City, MO 64111-3315 Ph: (816) 531-0930 |
News Archive
Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.
Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.
Children are less likely to be diagnosed with crossed eyes, a condition known as strabismus, if they live in poor communities, according to an analysis led by researchers at the University of Michigan's Kellogg Eye Center.
In a research paper recently uploaded to the preprint server medRxiv* by Havervall et al. (August 12th, 2021), neutralizing antibody titers towards wild-type SARS-CoV-2 and several variants of concern in individuals having either been vaccinated or infected with mild COVID-19 one year earlier are assessed, finding a reduced neutralization capacity against some strains.
› Verified 4 days ago
Nabih I Abdou, M.D., PH. D. Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 4330 Wornall Rd, Med Plaza Ii, 4th Floor, Kansas City, MO 64111 Phone: 816-531-0930 Fax: 816-753-2671 | |
Steve Warren Handoyo, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-983-6431 | |
Christian C Willingham, DO Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 4401 Wornall Rd, Kansas City, MO 64111 Phone: 816-932-2171 | |
Salman Abdullah Aljubran, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 3101 Broadway Blvd, Kansas City, MO 64111 Phone: 816-960-8885 Fax: 816-960-8888 | |
Aarti Pandya, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3000 Fax: 816-302-9939 | |
Dr. Bridgette L Jones, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 2401 Gillham Rd, Kansas City, MO 64108 Phone: 816-234-3097 |